title: [Post-marketing surveillance studies].
abstract: Approval of a drug on the market is typically considered as the successful endpoint of a long development phase. This often leads to reduced interest in further research for the indication approved, while in contrast the patient's as well as physician's interest in further research increases. This paper discusses the main areas of effectiveness, safety and post-marketing practice regarding sensible study types for the specific area and the potential gain of knowledge.
authors.affiliation: Bremer Institut für Präventionsforschung und Sozialmedizin, Linzer Strasse 8, Bremen. pigeot@bips.uni-bremen.de
authors.forename: I
authors.initials: I
authors.lastname: Pigeot
authors.forename: J
authors.initials: J
authors.lastname: Windeler
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D017326:Clinical Trials, Phase III as Topic; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008498:Medical Record Linkage; D008875:Middle Aged; D017891:Pharmacoepidemiology; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D012106:Research; D012449:Safety